Matching articles for "Fluzone"

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • September 16, 2024;  (Issue 1711)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • October 16, 2023;  (Issue 1687)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • October 3, 2022;  (Issue 1660)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):153-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • October 4, 2021;  (Issue 1634)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):153-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2020-2021

   
The Medical Letter on Drugs and Therapeutics • September 21, 2020;  (Issue 1607)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Tables 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):145-50 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2019-2020

   
The Medical Letter on Drugs and Therapeutics • October 21, 2019;  (Issue 1583)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):161-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2017-2018

   
The Medical Letter on Drugs and Therapeutics • October 9, 2017;  (Issue 1531)
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Med Lett Drugs Ther. 2017 Oct 9;59(1531):163-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2016-2017

   
The Medical Letter on Drugs and Therapeutics • October 10, 2016;  (Issue 1505)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Med Lett Drugs Ther. 2016 Oct 10;58(1505):127-30 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2015-2016

   
The Medical Letter on Drugs and Therapeutics • September 14, 2015;  (Issue 1477)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Med Lett Drugs Ther. 2015 Sep 14;57(1477):125-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2014-2015

   
The Medical Letter on Drugs and Therapeutics • October 13, 2014;  (Issue 1453)
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and...
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications.
Med Lett Drugs Ther. 2014 Oct 13;56(1453):97-9 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • June 1, 2014;  (Issue 142)
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on...
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.

Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Treat Guidel Med Lett. 2014 Jun;12(142):39-48 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2013-2014

   
The Medical Letter on Drugs and Therapeutics • September 16, 2013;  (Issue 1425)
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current...
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.
Med Lett Drugs Ther. 2013 Sep 16;55(1425):73-5 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2012-2013

   
The Medical Letter on Drugs and Therapeutics • October 1, 2012;  (Issue 1400)
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available...
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available for the current season. Chemoprophylaxis and treatment of influenza was discussed in an earlier issue.
Med Lett Drugs Ther. 2012 Oct 1;54(1400):77-8 | Show Full IntroductionHide Full Introduction

Adult Immunizations

   
The Medical Letter on Drugs and Therapeutics • December 1, 2011;  (Issue 112)
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed...
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.
Treat Guidel Med Lett. 2011 Dec;9(112):75-82 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2011-2012

   
The Medical Letter on Drugs and Therapeutics • October 17, 2011;  (Issue 1375)
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a...
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a new inactivated intradermal vaccine (Fluzone Intradermal) has been FDA-approved for use in adults 18-64 years old. An upcoming issue will review chemoprophylaxis and treatment of influenza.
Med Lett Drugs Ther. 2011 Oct 17;53(1375):81-3 | Show Full IntroductionHide Full Introduction

Seasonal Trivalent Influenza Vaccine for 2010-2011

   
The Medical Letter on Drugs and Therapeutics • October 4, 2010;  (Issue 1348)
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of...
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of influenza.
Med Lett Drugs Ther. 2010 Oct 4;52(1348):77-9 | Show Full IntroductionHide Full Introduction

Seasonal Trivalent Influenza Vaccine for 2009-2010

   
The Medical Letter on Drugs and Therapeutics • September 21, 2009;  (Issue 1321)
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing...
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing pandemic infection. The next issue of the Medical Letter will review the pandemic H1N1 vaccine.
Med Lett Drugs Ther. 2009 Sep 21;51(1321):73-4 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • April 1, 2009;  (Issue 80)
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed...
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.
Treat Guidel Med Lett. 2009 Apr;7(80):27-36 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2008-2009

   
The Medical Letter on Drugs and Therapeutics • October 6, 2008;  (Issue 1296)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications. Changes this year include a vaccine with three new...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications. Changes this year include a vaccine with three new influenza antigens and expanded age criteria to include all children 6 months to 18 years of age. An upcoming issue of The Medical Letter will review drugs for prophylaxis and treatment of influenza.
Med Lett Drugs Ther. 2008 Oct 6;50(1296):77-8 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2007-2008

   
The Medical Letter on Drugs and Therapeutics • October 8, 2007;  (Issue 1271)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications....
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Med Lett Drugs Ther. 2007 Oct 8;49(1271):81-3 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2006-2007

   
The Medical Letter on Drugs and Therapeutics • October 9, 2006;  (Issue 1245)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Med Lett Drugs Ther. 2006 Oct 9;48(1245):81-3 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • July 1, 2006;  (Issue 47)
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed...
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Treat Guidel Med Lett. 2006 Jul;4(47):47-54 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2005-2006

   
The Medical Letter on Drugs and Therapeutics • October 24, 2005;  (Issue 1220)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug prophylaxis and treatment of influenza.
Med Lett Drugs Ther. 2005 Oct 24;47(1220):85-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine 2004-2005

   
The Medical Letter on Drugs and Therapeutics • October 11, 2004;  (Issue 1193)
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating...
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating influenza A H3N2 strain (Fujian type) that had drifted antigenically from the H3N2 strain in the vaccine. The vaccine for the 2004-05 influenza season includes A/Wyoming/3/2003 (H3N2), which is antigenically equivalent to the Fujian strain, A/New Caledonia/20/99 (H1N1), which is unchanged, and a new B strain, either B/Jiangsu/10/2003 or B/Jilin/20/2003, which are both antigenically equivalent to B/Shanghai/361/2002.
Med Lett Drugs Ther. 2004 Oct 11;46(1193):83-4 | Show Full IntroductionHide Full Introduction

Influenza Prevention 2003-2004

   
The Medical Letter on Drugs and Therapeutics • September 29, 2003;  (Issue 1166)
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available...
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist, an intranasal vaccine and Fluzone, a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.
Med Lett Drugs Ther. 2003 Sep 29;45(1166):78-80 | Show Full IntroductionHide Full Introduction

Influenza Prevention 2002-2003

   
The Medical Letter on Drugs and Therapeutics • September 2, 2002;  (Issue 1138)
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal...
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal Wkly Rep 2002; 51:503).
Med Lett Drugs Ther. 2002 Sep 2;44(1138):75-6 | Show Full IntroductionHide Full Introduction

Influenza Prevention 2001-2002

   
The Medical Letter on Drugs and Therapeutics • September 17, 2001;  (Issue 1113)
The centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in vaccine...
The centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in vaccine availability. This year's delay is being attributed, in part, to the dicontinuation of the Fluogen (King) brand of vaccine. The 2001-02 vaccine will include A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Sichuan/379/99-like antigens.
Med Lett Drugs Ther. 2001 Sep 17;43(1113):81-2 | Show Full IntroductionHide Full Introduction

Problems With Influenza Vaccine

   
The Medical Letter on Drugs and Therapeutics • September 4, 2000;  (Issue 1086)
Production problems in some plants have delayed the availability of this year's influenza vaccine and may limit the total supply. These problems appear to be confined to the USA; no shortage is anticipated in...
Production problems in some plants have delayed the availability of this year's influenza vaccine and may limit the total supply. These problems appear to be confined to the USA; no shortage is anticipated in Canada
Med Lett Drugs Ther. 2000 Sep 4;42(1086):79-80 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1999-2000

   
The Medical Letter on Drugs and Therapeutics • September 10, 1999;  (Issue 1061)
...
A new trivalent influenza vaccine for intramuscular use is available for the 1999-2000 influenza season.
Med Lett Drugs Ther. 1999 Sep 10;41(1061):82-3 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1998-1999

   
The Medical Letter on Drugs and Therapeutics • September 11, 1998;  (Issue 1035)
A new trivalent influenza vaccine for intramuscular use is available for the 1998-1999 influenza season (Morbid Mortal Weekly Rep, 47, RR-6, May 1, 1998). Last year's vaccine was less effective than usual...
A new trivalent influenza vaccine for intramuscular use is available for the 1998-1999 influenza season (Morbid Mortal Weekly Rep, 47, RR-6, May 1, 1998). Last year's vaccine was less effective than usual because of the appearance of a new variant (A/Sydney/5/97) after selection of the vaccine antigens (Morbid Mortal Weekly Rep, 47:196, 1998). Antigens in the current vaccine are A/Beijing/262/95-like (H1N1); A/Sydney/5/97-like (H3N2), and B/Harbin/07/94, antigenically equivalent to B/Beijing/184/93. Both H1N1 and the H3N2 antigens are new this year. A highly publicized live attenuated influenza vaccine given by nasal spray (FluMist) has not yet been approved by the FDA and will not be available in the USA for use in the current influenza season (RB Belshe et al, N Engl J Med, 338:1405, 1998).
Med Lett Drugs Ther. 1998 Sep 11;40(1035):91-2 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1997-1998

   
The Medical Letter on Drugs and Therapeutics • September 12, 1997;  (Issue 1009)
A new trivalent influenza vaccine for intramuscular use is available for the 1997-1998 influenza season (Morbid Mortal Weekly Rep, 46 RR-9, April 25, 1997). Antigens in the current vaccine are ...
A new trivalent influenza vaccine for intramuscular use is available for the 1997-1998 influenza season (Morbid Mortal Weekly Rep, 46 RR-9, April 25, 1997). Antigens in the current vaccine are A/johannesburg/82/96, antigenically equivalent to A/Bayern/07/95 (H1N1); A/Nanchang/933/95, antigenically equivalent to A/Wuhan/359/95 (H3N2); and B/Harbin/07/94, antigenically equivalent to B/Beijing/184/93. Only the H1N1 antigen is new this year. A highly publicized nasal spray flu vaccine still has not been approved by the FDA and will not be available in the USA for use in the current influenza season.
Med Lett Drugs Ther. 1997 Sep 12;39(1009):85-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1996-1997

   
The Medical Letter on Drugs and Therapeutics • September 13, 1996;  (Issue 983)
The Centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in...
The Centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in vaccine availability. This years delay is being attributed, in part, to the discontinuation of the Fluogen (King) brand of vaccine. The 2001-02 vaccine will include A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Sichuan/379/99-like antigens (MMWR Morb Mortal Wkly Rep, 50 RR-4:5, April 30, 2001).
Med Lett Drugs Ther. 1996 Sep 13;38(983):86 | Show Full IntroductionHide Full Introduction

Influenza Vaccine

   
The Medical Letter on Drugs and Therapeutics • September 1, 1995;  (Issue 956)
A new trivalent influenza vaccine is available for the 1995-1996 influenza season. Influenza vaccine, made from inactivated virus grown in eggs, is recommended especially for elderly and high-risk patients,...
A new trivalent influenza vaccine is available for the 1995-1996 influenza season. Influenza vaccine, made from inactivated virus grown in eggs, is recommended especially for elderly and high-risk patients, their household contacts and health-care personnel who may come in contact with such patients (Morbid Mortal Weekly Rep, 44, RR-3, April 21, 1995). Antigens in the current vaccine are derived from A/Texas/36/91/ (H1N1), A/Johannesburg and B/Harbin antigens are new this year.
Med Lett Drugs Ther. 1995 Sep 1;37(956):78 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1995-1995

   
The Medical Letter on Drugs and Therapeutics • September 16, 1994;  (Issue 931)
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong- Kong/330/01-like (MMWR Morb Mortal...
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong- Kong/330/01-like (MMWR Morb Mortal Wkly Rep 2002; 51:503).
Med Lett Drugs Ther. 1994 Sep 16;36(931):84 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1993-1994

   
The Medical Letter on Drugs and Therapeutics • September 17, 1993;  (Issue 905)
A new trivalent influenza vaccine is available for the 1993-1994 influenza season. Vaccination may be even more important than usual this year because of the appearance late in last year's flu season of a new...
A new trivalent influenza vaccine is available for the 1993-1994 influenza season. Vaccination may be even more important than usual this year because of the appearance late in last year's flu season of a new antigenic variant, which was associated with an increase in deaths (Morbid Mortal Weekly Rep, 42:385, May 28, 1993). Influenza vaccine is recommended especially for the elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients (Morbid Mortal Weekly Rep, 42,RR-6, May 14, 1993).
Med Lett Drugs Ther. 1993 Sep 17;35(905):89-90 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1992-1993

   
The Medical Letter on Drugs and Therapeutics • September 18, 1992;  (Issue 879)
A new trivalent influenza vaccine is now available for the 1992-1993 influenza season (Morbid Mortal Weekly Rep, 41, RR-9:1, May 15, 1992). Vaccination is recommended especially for elderly and high-risk...
A new trivalent influenza vaccine is now available for the 1992-1993 influenza season (Morbid Mortal Weekly Rep, 41, RR-9:1, May 15, 1992). Vaccination is recommended especially for elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients. Antigens in the current vaccine are derived from A/Texas/36/91 (H1N1), A/Beijing/353/89 (H3N2), and B/Panama/45/90. The A/Texas/36/91 (H1N1) strain is new this year.
Med Lett Drugs Ther. 1992 Sep 18;34(879):90 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1991-1992

   
The Medical Letter on Drugs and Therapeutics • September 6, 1991;  (Issue 852)
A new trivalent influenza vaccine is now available for the 1991-1992 influenza season (Morbid Mortal Weekly Rep, 40, RR-6:1, May 24, 1991). Vaccination is recommended especially for elderly and high-risk...
A new trivalent influenza vaccine is now available for the 1991-1992 influenza season (Morbid Mortal Weekly Rep, 40, RR-6:1, May 24, 1991). Vaccination is recommended especially for elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients. Antigens in the current vaccine are derived from A/Taiwan/1/86 (H1N1), A/Beijing/353/89 (H3N2), and B/Panama/45/90 are new this year.
Med Lett Drugs Ther. 1991 Sep 6;33(852):86 | Show Full IntroductionHide Full Introduction

Influenza Vaccine, 1990-1991

   
The Medical Letter on Drugs and Therapeutics • September 7, 1990;  (Issue 826)
A new trivalent influenza vaccine is now available for the 1990-1991 influenza season (Morbid Mortal Weekly Rep, 39, RR7:1, May 11, 1990). Vaccination is recommended especially for elderly and high-risk...
A new trivalent influenza vaccine is now available for the 1990-1991 influenza season (Morbid Mortal Weekly Rep, 39, RR7:1, May 11, 1990). Vaccination is recommended especially for elderly and high-risk patients, their household contacts, and health-care personnel who may come in contact with such patients. Antigens in the vaccine include A/Taiwan/1/86 (H1N1), A/Shanghai/16/89 (H3N2), and B/Yamagata/16/88 is new this year.
Med Lett Drugs Ther. 1990 Sep 7;32(826):86 | Show Full IntroductionHide Full Introduction

Routine Immunization for Adult

   
The Medical Letter on Drugs and Therapeutics • June 1, 1990;  (Issue 819)
Six vaccines are recommended for routine use in adults living in the USA (Guide for Adult Immunization, 2nd ed, Philadelphia:American College of Physicians, 1990). Immunization recommendations for travel...
Six vaccines are recommended for routine use in adults living in the USA (Guide for Adult Immunization, 2nd ed, Philadelphia:American College of Physicians, 1990). Immunization recommendations for travel outside the USA were published in The Medical Letter, volume 32, page 33, April 6, 1990.
Med Lett Drugs Ther. 1990 Jun 1;32(819):54-6 | Show Full IntroductionHide Full Introduction

Influenza Prevention, 1989-1990

   
The Medical Letter on Drugs and Therapeutics • October 20, 1989;  (Issue 803)
A new trivalent inactivated influenza vaccine is now available for the 1989-1990 influenza season (Morbid Mortal Weekly Rep, 38:297, May 5, 1989: Can Med Assoc J, 141:425, Spet 1, 1989). Antigens in this...
A new trivalent inactivated influenza vaccine is now available for the 1989-1990 influenza season (Morbid Mortal Weekly Rep, 38:297, May 5, 1989: Can Med Assoc J, 141:425, Spet 1, 1989). Antigens in this years's Vaccine are A/Taiwan/1/86 (H1N1), A/Shanghai/11/87 (H3N2), and B/Yamagata/16/88. The A/Shanghai and B/Yamagata are new strains this year. The vaccine is available in the USA as a split-virus (subvirion) or whole virus preparation from Squibb (Fluzone), as a split-virus preparation from parke-davis (Fluogen) and Wyeth-Ayerst (Influenza Virus Vaccine, Trivalent), and as a purified-surface-antigen formulations may be less likely to cause adverse reactions, especially in children; whole-virus vaccines may be slighltly more antigenic. Vaccine from previous years should not be used.
Med Lett Drugs Ther. 1989 Oct 20;31(803):95-6 | Show Full IntroductionHide Full Introduction

Influenza Prevention, 1988-1989

   
The Medical Letter on Drugs and Therapeutics • August 26, 1988;  (Issue 773)
A new trivalent inactivated influenza vaccine is now available for the 1988-1989 influenza season (Morbid Mortal Weekly Rep, 37:357, June 17, 1988). Antigens in this year's vaccine are A/Taiwan/1/86 (H1N1),...
A new trivalent inactivated influenza vaccine is now available for the 1988-1989 influenza season (Morbid Mortal Weekly Rep, 37:357, June 17, 1988). Antigens in this year's vaccine are A/Taiwan/1/86 (H1N1), A/Sichuan/2/87 (H3N2), and B/Victoria/2/87. The A/Sichuan is a new strain that caused last year's large outbreak of the disease. The vaccine is available in the USA as a split-virus (Subvirion) or whole virus preparation from Squibb (Fluzone), and as a split-virus preparation from Parke-Davis (Fluogen) and Wyeth (Influenza Virus Vaccine, Trivalent). Split-virus vaccines may be slightly more antigenic. Vaccine from previous years should not be used.
Med Lett Drugs Ther. 1988 Aug 26;30(773):83-4 | Show Full IntroductionHide Full Introduction